Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 3/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.38 |
| ▸ | HRH2 | P25021 | 10/20 | 0.35 |
| ▸ | HRH1 | P35367 | 10/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | PARP12 | Q9H0J9 | 1/20 | 0.34 |
| ▸ | THRA | P10827 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10099812 | 0.92 | ITGB3 (0.36) | ITGB3ITGA2BHRH2HRH1HDAC8 | |
| SCHEMBL557854 | 0.92 | ITGB3 (0.36) | ITGB3ITGA2BHRH2HRH1HDAC8 | |
| SCHEMBL557969 | 0.92 | ITGB3 (0.36) | ITGB3ITGA2BHRH2HRH1HDAC8 | |
| SCHEMBL1362154 | 0.85 | ITGB3 (0.37) | ITGB3ITGA2BHRH2HRH1HDAC8 | |
| SCHEMBL2924740 | 0.85 | KMT2A (0.37) | — | |
| SCHEMBL1744893 | 0.85 | GPR119 (0.41) | HRH2HRH1THRATHRBGPR119 | |
| SCHEMBL557680 | 0.85 | GPR119 (0.41) | HRH2HRH1THRATHRBGPR119 | |
| SCHEMBL1744957 | 0.84 | ITGB3 (0.46) | ITGB3ITGA2BHDAC8PARP12 | |
| SCHEMBL558014 | 0.81 | PPARA (0.44) | THRATHRBGPR119 | |
| SCHEMBL21980209 | 0.81 | ITGB3 (0.44) | ITGB3ITGA2BHDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8933021-B2 | Insulin derivative | NOVO NORDISK A/S (DK) | 2015-01-13 | — | — | US | disclosed |
| US-20090239785-A1 | Insulin Derivative | NOVO NORDISK A/S (DK) | 2009-09-24 | — | — | US | disclosed |
| EP-2015770-A2 | INSULIN DERIVATIVE | Novo Nordisk A/S (DK) | 2009-01-21 | — | — | EP | disclosed |
| WO-2007128817-A2 | INSULIN DERIVATIVE | NOVO NORDISK A/S (DK) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239785-A1 | Insulin Derivative | IAPP, INSR, GPR119 | ITGB3 4146/4885ITGA2B 4474/4885HRH2 3672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.